BCMA Heavy Chain-Only Antibody Design Without Light Chains
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibodies for treating B-cell disorders like multiple myeloma and systemic lupus erythematosus are limited by the need for light chains, which can complicate production and stability, and there is a lack of effective therapies targeting BCMA with high specificity and affinity.
Innovation Solution
Development of heavy chain-only antibodies (HCAbs) that specifically bind to BCMA, lacking the CH1 domain and comprising defined CDR sequences, enabling high affinity and specificity without light chains, and can be used in bispecific or CAR-T formats.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional antibodies with light chains are used, then structural stability is maintained, but production complexity and manufacturing difficulty increase
Solution Approach 1:
The patent extracts and removes the light chain component from the conventional antibody structure, creating heavy chain-only antibodies. This extraction eliminates the need for light chains while maintaining the essential antigen-binding function through the heavy chain variable region, thereby simplifying production without completely sacrificing structural stability
Solution Approach 2:
The patent changes the structural parameters of the antibody by deleting the CH1 domain and light chain components, transforming the conventional IgG structure into a heavy chain-only format. This parameter change simplifies the molecular composition while maintaining functional integrity through optimized heavy chain design
2Ease of manufacture
If heavy chain-only antibodies are designed, then production complexity is reduced, but binding affinity and specificity may be compromised
Solution Approach 1:
The patent applies local quality optimization by focusing enhancement efforts on the heavy chain variable region, particularly the CDR loops. By optimizing the local structure and composition of the antigen-binding site with specific amino acid sequences, the patent achieves high binding affinity and specificity despite the simplified overall structure
Solution Approach 2:
The patent creates a composite antibody structure combining optimized heavy chain variable regions with engineered constant regions. This composite design integrates the antigen-binding functionality with stabilized structural elements, achieving both simplified production and reliable binding performance
3Adaptability or versatility
If CH1 domain is removed to create HCAbs, then light chain dependency is eliminated, but structural completeness is reduced
Solution Approach 1:
The patent segments the antibody structure into independent functional modules: the heavy chain variable region for antigen binding and the engineered constant regions for structural support and effector functions. This segmentation allows the CH1 domain to be removed while maintaining structural integrity through the remaining constant regions
Solution Approach 2:
The patent introduces engineered constant regions (CH2, CH3) as intermediary structural elements that compensate for the removed CH1 domain. These intermediary elements provide the necessary structural framework and stability that would otherwise be provided by the CH1-light chain complex
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The HCAbs provide high binding affinity and specificity to BCMA, offering therapeutic potential for B-cell disorders by modulating BCMA activity and inducing targeted cell killing, with applications in multiple myeloma and systemic lupus erythematosus treatment.
Implementation Method 1
the association of the heavy chain and light chain is due in part to a hydrophobic interaction between the light chain constant region and the CH1 constant domain of the heavy chain
Data Source
AI summary
Anti-BCMA heavy chain-only antibodies (HCAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.